| Citation: |
BAO Zhen, QIAO Yahong. Recombinant ficolin 3 expression in non-small cell lung cancer and its biological function[J]. Journal of Clinical Medicine in Practice, 2024, 28(14): 18-23. DOI: 10.7619/jcmp.20240922
|
To explore the potential mechanism of recombinant ficolin 3(FCN3) in regulating non-small cell lung cancer cell line A549.
Bioinformatics analysis of FCN3 was performed using online software, and its overexpression vector and siRNA interference system were constructed.CCK8 assay and flow cytometry were used to detect the effects of overexpression and knockdown of FCN3 on the proliferation and apoptosis of A549 cells.Real-time fluorescent quantitative polymerase chain reaction was used to detect the influence of FCN3 on the expression of lung adenocarcinoma-related genes[Chromobox Homolog 5(CBX3), Cyclin-Dependent Kinase Inhibitor 3(CDKN3) and Baculoviral IAP Repeat-Containing Protein 5(BIRC5)].
After overexpression of FCN3, the apoptosis level of A549 cells increased, and the proliferation level decreased (P < 0.05).After knockdown of FCN3, the apoptosis level of A549 cells decreased, and the proliferation level increased (P < 0.05).Overexpression of FCN3 inhibited the expression of CBX3, CDKN3 as well as BIRC5 mRNA, and promoted the expression of FABP4 mRNA; knockdown of FCN3 promoted the expression of CBX3, CDKN3 as well as BIRC5 mRNA, and inhibited the expression of FABP4 mRNA.
FCN3 can inhibit the proliferation of A549 cells and promote their apoptosis.FCN3 may serve as a potential therapeutic target for non-small cell lung cancer.
| [1] |
WOLF A M D, OEFFINGER K C, SHIH T Y, et al. Screening for lung cancer: 2023 guideline update from the American Cancer Society[J]. CA Cancer J Clin, 2024, 74(1): 50-81. doi: 10.3322/caac.21811
|
| [2] |
HUANG S G, YANG J, SHEN N, et al. Artificial intelligence in lung cancer diagnosis and prognosis: current application and future perspective[J]. Semin Cancer Biol, 2023, 89: 30-37. doi: 10.1016/j.semcancer.2023.01.006
|
| [3] |
张吉炯, 张健. 微小RNA-508-3p靶向调控配对盒基因2影响肺癌细胞生物学特性的分子机制研究[J]. 实用临床医药杂志, 2022, 26(2): 62-68, 75. doi: 10.7619/jcmp.20213451
|
| [4] |
GARRED P, HONORÉ C, MA Y J, et al. MBL2, FCN1, FCN2 and FCN3-The genes behind the initiation of the lectin pathway of complement[J]. Mol Immunol, 2009, 46(14): 2737-2744. doi: 10.1016/j.molimm.2009.05.005
|
| [5] |
MICHALSKI M, SZALA A, SWIERZKO A S, et al. H-ficolin (ficolin-3) concentrations and FCN3 gene polymorphism in neonates[J]. Immunobiology, 2012, 217(7): 730-737. doi: 10.1016/j.imbio.2011.12.004
|
| [6] |
MUNTHE-FOG L, HUMMELSH∅J T, HONORÉ C, et al. Immunodeficiency associated with FCN3 mutation and ficolin-3 deficiency[J]. N Engl J Med, 2009, 360(25): 2637-2644. doi: 10.1056/NEJMoa0900381
|
| [7] |
VILLASEÑOR-ALTAMIRANO A B, MORETTO M, MALDONADO M, et al. PulmonDB: a curated lung disease gene expression database[J]. Sci Rep, 2020, 10(1): 514. doi: 10.1038/s41598-019-56339-5
|
| [8] |
KIM A, LIM S M, KIM J H, et al. Integrative genomic and transcriptomic analyses of tumor suppressor genes and their role on tumor microenvironment and immunity in lung squamous cell carcinoma[J]. Front Immunol, 2021, 12: 598671. doi: 10.3389/fimmu.2021.598671
|
| [9] |
GASTEIGER E, GATTIKER A, HOOGLAND C, et al. ExPASy: the proteomics server for in-depth protein knowledge and analysis[J]. Nucleic Acids Res, 2003, 31(13): 3784-3788. doi: 10.1093/nar/gkg563
|
| [10] |
KÄLL L, KROGH A, SONNHAMMER E L L. Advantages of combined transmembrane topology and signal peptide prediction: the Phobius web server[J]. Nucleic Acids Res, 2007, 35(Web Server issue): W429-W432.
|
| [11] |
LUO J S, HUANG J, ZENG D L, et al. A defensin-like protein drives cadmium efflux and allocation in rice[J]. Nat Commun, 2018, 9(1): 645. doi: 10.1038/s41467-018-03088-0
|
| [12] |
MOHL J E, GERKEN T A, LEUNG M Y. ISOGlyP: de novo prediction of isoform-specific mucin-type O-glycosylation[J]. Glycobiology, 2021, 31(3): 168-172. doi: 10.1093/glycob/cwaa067
|
| [13] |
GAO J, CHENG A C, WANG M S. Bioinformatics analysis and characteristics of US2 protein encoded by the newly identified US2 gene of duck enteritis virus[J]. Adv Mater Res, 2012, 424/425: 493-497. doi: 10.4028/www.scientific.net/AMR.424-425.493
|
| [14] |
SZKLARCZYK D, FRANCESCHINI A, WYDER S, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life[J]. Nucleic Acids Res, 2015, 43(Database issue): D447-D452.
|
| [15] |
ANGAMUTHU K, PIRAMANAYAGAM S. Evaluation of in silico protein secondary structure prediction methods by employing statistical techniques[J]. Biomed Biotechnol Res J, 2017, 1(1): 29. doi: 10.4103/bbrj.bbrj_28_17
|
| [16] |
WATERHOUSE A, BERTONI M, BIENERT S, et al. SWISS-MODEL: homology modelling of protein structures and complexes[J]. Nucleic Acids Res, 2018, 46(W1): W296-W303. doi: 10.1093/nar/gky427
|
| [17] |
LIVAK K J, SCHMITTGEN T D. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C(T)) Method[J]. Methods, 2001, 25(4): 402-408. doi: 10.1006/meth.2001.1262
|
| [18] |
GOLDSTRAW P, BALL D, JETT J R, et al. Non-small-cell lung cancer[J]. Lancet, 2011, 378(9804): 1727-1740. doi: 10.1016/S0140-6736(10)62101-0
|
| [19] |
ZAPPA C, MOUSA S A. Non-small cell lung cancer: current treatment and future advances[J]. Transl Lung Cancer Res, 2016, 5(3): 288-300. doi: 10.21037/tlcr.2016.06.07
|
| [20] |
MATSUSHITA M, FUJITA T. The role of ficolins in innate immunity[J]. Immunobiology, 2002, 205(4/5): 490-497.
|
| [21] |
FERRÍN G, RANCHAL I, LLAMOZA C, et al. Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV-infected cirrhotic patients by 2-D DIGE[J]. Liver Int, 2014, 34(3): 438-446. doi: 10.1111/liv.12277
|
| [22] |
ANDERSEN J D, BOYLAN K L, XUE F S, et al. Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis[J]. Electrophoresis, 2010, 31(4): 599-610. doi: 10.1002/elps.200900441
|
| [23] |
METZGER M L, MICHELFELDER I, GOLDACKER S, et al. Low ficolin-2 levels in common variable immunodeficiency patients with bronchiectasis[J]. Clin Exp Immunol, 2015, 179(2): 256-264. doi: 10.1111/cei.12459
|
| [24] |
HERSHKOVITZ E, ARAFAT M, LOEWENTHAL N, et al. Combined adrenal failure and testicular adrenal rest tumor in a patient with nicotinamide nucleotide transhydrogenase deficiency[J]. J Pediatr Endocrinol Metab, 2015, 28(9/10): 1187-1190.
|
| [25] |
LU J Y, LI M, ZHANG R, et al. A common genetic variant of FCN3/CD164L2 is associated with essential hypertension in a Chinese population[J]. Clin Exp Hypertens, 2012, 34(5): 377-382. doi: 10.3109/10641963.2012.665538
|
| [26] |
JANG H, JUN Y, KIM S, et al. FCN3 functions as a tumor suppressor of lung adenocarcinoma through induction of endoplasmic reticulum stress[J]. Cell Death Dis, 2021, 12(4): 407. doi: 10.1038/s41419-021-03675-y
|
| [27] |
XIE X B, NING Y, LONG J, et al. Diverse CBX family members as potential prognostic biomarkers in non-small-cell lung cancer[J]. FEBS Open Bio, 2020, 10(10): 2206-2215. doi: 10.1002/2211-5463.12971
|
| [28] |
CRESS W D, YU P, WU J. Expression and alternative splicing of the cyclin-dependent kinase inhibitor-3 gene in human cancer[J]. Int J Biochem Cell Biol, 2017, 91(Pt B): 98-101.
|
| [29] |
ZU Y K, BAN J B, XIA Z X, et al. Genetic variation in a miR-335 binding site in BIRC5 alters susceptibility to lung cancer in Chinese Han populations[J]. Biochem Biophys Res Commun, 2013, 430(2): 529-534. doi: 10.1016/j.bbrc.2012.12.001
|
| [30] |
TANG Z Y, SHEN Q, XIE H, et al. Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC)[J]. Oncotarget, 2016, 7(29): 46253-46262. doi: 10.18632/oncotarget.10086
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: